This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Newman, S. P. Articles by Purohit, A. Search for Related Content PubMed PubMed Citation Articles by Newman, S. P. Articles by Purohit, A.

STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells

Authors' Affiliations: ¹ Endocrinology and Metabolic Medicine and Sterix, Ltd., Faculty of Medicine, Imperial College London, St Mary's Hospital, London, United Kingdom; ² XenTech, Evry, France; ³ IPSEN Research Laboratories, Institut Henri Beaufour, Les Ulis Cedex, France; and ⁴ Medicinal Chemistry and Sterix, Ltd., Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom

Requests for reprints: Simon P. Newman, Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St Mary's Hospital, London W2 1NY, United Kingdom. Phone: 44-207-886-1210; Fax: 44-207-886-1790; E-mail: simon.newman{at}imperial.ac.uk.

Purpose: The aim of these studies was to characterize the action of STX140 in a P-glycoprotein–overexpressing tumor cell line both in vitro and in vivo. In addition, its efficacy was determined against xenografts derived from patients who failed docetaxel therapy.

Experimental Design: The effects of STX140, Taxol, and 2-methoxyestradiol (2-MeOE2) on cell proliferation, cell cycle, and apoptosis were assessed in vitro in drug-resistant cells (MCF-7_DOX) and the parental cell line (MCF-7_WT). Mice bearing an MCF-7_DOX tumor on one flank and an MCF-7_WT tumor on the other flank were used to assess the in vivo efficacy. Furthermore, the responses to STX140 of three xenografts, derived from drug-resistant patients, were assessed.

Results: In this study, STX140 caused cell cycle arrest, cyclin B1 induction, and subsequent apoptosis of both MCF-7_DOX and MCF-7_WT cells. Taxol and 2-MeOE2 were only active in the MCF-7_WT parental cell line. Although both STX140 and Taxol inhibited the growth of xenografts derived from MCF-7_WT cells, only STX140 inhibited the growth of tumors derived from MCF-7_DOX cells. 2-MeOE2 was ineffective at the dose tested against both tumor types. Two out of the three newly derived docetaxel-resistant xenografts, including a metastatic triple-negative tumor, responded to STX140 but not to docetaxel treatment.

Conclusions: STX140 shows excellent efficacy in both MCF-7_WT and MCF-7_DOX breast cancer xenograft models, in contrast to Taxol and 2-MeOE2. The clinical potential of STX140 was further highlighted by the efficacy seen in xenografts recently derived from patients who had failed on taxane therapy.

This article has been cited by other articles:

				A.-M. Liberatore, H. Coulomb, D. Pons, O. Dutruel, P. G. Kasprzyk, M. Carlson, A. S. Nelson, S. P. Newman, C. Stengel, P. Auvray, et al. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents Mol. Cancer Ther., August 1, 2008; 7(8): 2426 - 2434. [Abstract] [Full Text] [PDF]